Table of Contents Author Guidelines Submit a Manuscript
Obstetrics and Gynecology International
Volume 2013, Article ID 479541, 5 pages
http://dx.doi.org/10.1155/2013/479541
Review Article

The Estrogen Receptor Joins Other Cancer Biomarkers as a Predictor of Outcome

Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, IA 52242, USA

Received 17 June 2013; Accepted 10 September 2013

Academic Editor: Eric Prossnitz

Copyright © 2013 Kimberly K. Leslie et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Cancer Facts and Figures, 2013, http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf.
  2. Y. M. Huet-Hudson, C. Chakraborty, S. K. De, Y. Suzuki, G. K. Andrews, and S. K. Dey, “Estrogen regulates the synthesis of epidermal growth factor in mouse uterine epithelial cells,” Molecular Endocrinology, vol. 4, no. 3, pp. 510–523, 1990. View at Google Scholar · View at Scopus
  3. R. B. Lingham, G. M. Stancel, and D. S. Loose-Mitchell, “Estrogen regulation of epidermal growth factor receptor messenger ribonucleic acid,” Molecular Endocrinology, vol. 2, no. 3, pp. 230–235, 1988. View at Google Scholar · View at Scopus
  4. L. J. Murphy, L. C. Murphy, and H. G. Friesen, “Estrogen induces insulin-like growth factor-I expression in the rat uterus,” Molecular Endocrinology, vol. 1, no. 7, pp. 445–450, 1987. View at Google Scholar · View at Scopus
  5. A. Weisz and F. Bresciani, “Estrogen induces expression of c-fos and c-myc protooncogenes in rat uterus,” Molecular Endocrinology, vol. 2, no. 9, pp. 816–824, 1988. View at Google Scholar · View at Scopus
  6. A. H. Charpentier, A. K. Bednarek, R. L. Daniel et al., “Effects of estrogen on global gene expression: identification of novel targets of estrogen action,” Cancer Research, vol. 60, no. 21, pp. 5977–5983, 2000. View at Google Scholar · View at Scopus
  7. K. R. Coser, J. Chesnes, J. Hur, S. Ray, K. J. Isselbacher, and T. Shioda, “Global analysis of ligand sensitivity of estrogen inducible and suppressible genes in MCF7/BUS breast cancer cells by DNA microarray,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 2, pp. 13994–13999, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Frasor, J. M. Danes, B. Komm, K. C. N. Chang, C. Richard Lyttle, and B. S. Katzenellenbogen, “Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype,” Endocrinology, vol. 144, no. 10, pp. 4562–4574, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Kininis, B. S. Chen, A. G. Diehl et al., “Genomic analyses of transcription factor binding, histone acetylation, and gene expression reveal mechanistically distinct classes of estrogen-regulated promoters,” Molecular and Cellular Biology, vol. 27, no. 14, pp. 5090–5104, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. C.-Y. Lin, V. B. Vega, J. S. Thomsen et al., “Whole-genome cartography of estrogen receptor alpha binding sites,” PLoS Genetics, vol. 3, no. 6, article e87, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. J. D. Stender, J. Frasor, B. Komm, K. C. N. Chang, W. L. Kraus, and B. S. Katzenellenbogen, “Estrogen-regulated gene networks in human breast cancer cells: involvement of E2F1 in the regulation of cell proliferation,” Molecular Endocrinology, vol. 21, no. 9, pp. 2112–2123, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. J. S. Carroll, C. A. Meyer, J. Song et al., “Genome-wide analysis of estrogen receptor binding sites,” Nature Genetics, vol. 38, no. 11, pp. 1289–1297, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. W.-J. Welboren, M. A. Van Driel, E. M. Janssen-Megens et al., “ChIP-Seq of ERα and RNA polymerase II defines genes differentially responding to ligands,” EMBO Journal, vol. 28, no. 10, pp. 1418–1428, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. M. E. Sherman, S. Sturgeon, L. Brinton, and R. J. Kurman, “Endometrial cancer chemoprevention: implications of diverse pathways of carcinogenesis,” Journal of Cellular Biochemistry, vol. 59, no. 23, pp. 160–164, 1995. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Enomoto, M. Inoue, A. O. Perantoni et al., “K-ras activation in premalignant and malignant epithelial lesions of the human uterus,” Cancer Research, vol. 51, no. 19, pp. 5308–5314, 1991. View at Google Scholar · View at Scopus
  16. J. I. Risinger, A. K. Hayes, A. Berchuck, and J. C. Barrett, “PTEN/MMAC1 mutations in endometrial cancers,” Cancer Research, vol. 57, no. 21, pp. 4736–4738, 1997. View at Google Scholar · View at Scopus
  17. G. L. Mutter, M.-C. Lin, J. T. Fitzgerald et al., “Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers,” Journal of the National Cancer Institute, vol. 92, no. 11, pp. 924–931, 2000. View at Google Scholar · View at Scopus
  18. A. J. Ryan, B. Susil, T. W. Jobling, and M. K. Oehler, “Endometrial cancer,” Cell and Tissue Research, vol. 322, no. 1, pp. 53–61, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Kandoth, N. Schultz, A. D. Cherniack et al., “Integrated genomic characterization of endometrial carcinoma,” Nature, vol. 497, no. 7447, pp. 67–73.
  20. “Integrated genomic analyses of ovarian carcinoma,” Nature, vol. 474, no. 7353, pp. 609–615, 2011.
  21. H. Liang, L. W. Cheung, J. Li et al., “Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer,” Genome Research, vol. 22, no. 11, pp. 2120–2129, 2012. View at Google Scholar
  22. U. M. Moll, E. Chalas, M. Auguste, D. Meaney, and J. Chumas, “Uterine papillary serous carcinoma evolves via a p53-driven pathway,” Human Pathology, vol. 27, no. 12, pp. 1295–1300, 1996. View at Publisher · View at Google Scholar · View at Scopus
  23. W. Zheng, P. Cao, M. Zheng, E. E. Kramer, and T. A. Godwin, “p53 Overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes,” Gynecologic Oncology, vol. 61, no. 2, pp. 167–174, 1996. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Kounelis, N. Kapranos, E. Kouri, D. Coppola, H. Papadaki, and M. W. Jones, “Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature,” Modern Pathology, vol. 13, no. 4, pp. 379–388, 2000. View at Google Scholar · View at Scopus
  25. K. K. Leslie, M.-P. Stein, N. S. Kumar et al., “Progesterone receptor isoform identification and subcellular localization in endometrial cancer,” Gynecologic Oncology, vol. 96, no. 1, pp. 32–41, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Zhao, M. Choi, J. D. Overton et al., “Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma,” Proceedings of the National Academy of Sciences of USA, vol. 110, no. 8, pp. 2916–2921, 2013. View at Google Scholar
  27. M. Le Gallo, A. J. O'Hara, M. L. Rudd et al., “Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes,” Nature Genetics, vol. 44, no. 12, pp. 1310–1315, 2012. View at Google Scholar
  28. J. Häring, M. Skrzypczak, A. Stegerer et al., “Estrogen receptor β transcript variants associate with oncogene expression in endometrial cancer,” International Journal of Molecular Medicine, vol. 29, no. 6, pp. 1127–1136, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. V. Jongen, J. Briët, R. de Jong et al., “Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer,” Gynecologic Oncology, vol. 112, no. 3, pp. 537–542, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. I. Mylonas, J. Makovitzky, K. Friese, and U. Jeschke, “Immunohistochemical labelling of steroid receptors in normal and malignant human endometrium,” Acta Histochemica, vol. 111, no. 4, pp. 349–359, 2009. View at Google Scholar · View at Scopus
  31. C. M. Revankar, C. M. Vines, D. F. Cimino, and E. R. Prossnitz, “Arrestins block G protein-coupled receptor-mediated apoptosis,” Journal of Biological Chemistry, vol. 279, no. 23, pp. 24578–24584, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. H. O. Smith, K. K. Leslie, M. Singh et al., “GPR30: a novel indicator of poor survival for endometrial carcinoma,” American Journal of Obstetrics and Gynecology, vol. 196, no. 4, pp. 386.e1–386.e11, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. E. J. Filardo, “Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer,” Journal of Steroid Biochemistry and Molecular Biology, vol. 80, no. 2, pp. 231–238, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. E. J. Filardo, J. A. Quinn, A. Raymond Frackelton Jr., and K. I. Bland, “Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis,” Molecular Endocrinology, vol. 16, no. 1, pp. 70–84, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. E. R. Prossnitz, “Novel roles for arrestins in the post-endocytic trafficking of G protein-coupled receptors,” Life Sciences, vol. 75, no. 8, pp. 893–899, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. J. F. Savouret, A. Chauchereau, M. Misrahi et al., “The progesterone receptor: biological effects of progestins and antiprogestins,” Human Reproduction, vol. 9, no. 1, pp. 7–11, 1994. View at Google Scholar · View at Scopus
  37. J.-F. Savouret, M. Rauch, G. Redeuilh et al., “Interplay between estrogens, progestins, retinoic acid and AP-1 on a single regulatory site in the progesterone receptor gene,” Journal of Biological Chemistry, vol. 269, no. 46, pp. 28955–28962, 1994. View at Google Scholar · View at Scopus
  38. M. Singh, R. J. Zaino, V. J. Filiaci, and K. K. Leslie, “Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: A Gynecologic Oncology Group Study,” Gynecologic Oncology, vol. 106, no. 2, pp. 325–333, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. D. Dai, E. S. Litman, E. Schonteich, and K. K. Leslie, “Progesterone regulation of activating protein-1 transcriptional activity: a possible mechanism of progesterone inhibition of endometrial cancer cell growth,” Journal of Steroid Biochemistry and Molecular Biology, vol. 87, no. 2-3, pp. 123–131, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. D. Dai, D. M. Wolf, E. S. Litman, M. J. White, and K. K. Leslie, “Progesterone inhibits human endometrial cancer cell growth and invasiveness: down-regulation of cellular adhesion molecules through progesterone B receptors1,” Cancer Research, vol. 62, no. 3, pp. 881–886, 2002. View at Google Scholar · View at Scopus
  41. D. Dai, N. S. Kumar, D. M. Wolf, and K. K. Leslie, “Molecular tools to reestablish progestin control of endometrial cancer cell proliferation,” American Journal of Obstetrics and Gynecology, vol. 184, no. 5, pp. 790–797, 2001. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Davies, D. Dai, G. Pickett, and K. K. Leslie, “Gene regulation profiles by progesterone and dexamethasone in human endometrial cancer Ishikawa H cells,” Gynecologic Oncology, vol. 101, no. 1, pp. 62–70, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Davies, D. Dai, D. M. Wolf, and K. K. Leslie, “Immunomodulatory and transcriptional effects of progesterone through progesterone a and B receptors in Hec50co poorly differentiated endometrial cancer cells,” Journal of the Society for Gynecologic Investigation, vol. 11, no. 7, pp. 494–499, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Yang, K. W. Thiel, K. De Geest, and K. K. Leslie, “Endometrial cancer: reviving progesterone therapy in the molecular age,” Discovery Medicine, vol. 12, no. 64, pp. 205–212, 2011. View at Google Scholar · View at Scopus
  45. S. Yang, K. W. Thiel, and K. K. Leslie, “Progesterone: the ultimate endometrial tumor suppressor,” Trends in Endocrinology and Metabolism, vol. 22, no. 4, pp. 145–152, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. C. Aghajanian, M. W. Sill, K. M. Darcy et al., “Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: A Gynecologic Oncology Group Study,” Journal of Clinical Oncology, vol. 29, no. 16, pp. 2259–2265, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. A. A. Garcia, M. W. Sill, H. A. Lankes et al., “A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group Study,” Gynecologic Oncology, vol. 124, no. 3, pp. 569–574, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. K. K. Leslie, M. W. Sill, E. Fischer et al., “A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study,” Gynecologic Oncology, vol. 129, no. 3, pp. 486–494, 2013. View at Google Scholar
  49. K. K. Leslie, M. W. Sill, H. A. Lankes et al., “Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer,” Gynecologic Oncology, vol. 127, no. 2, pp. 345–350, 2012. View at Google Scholar
  50. M. Singh, K. M. Darcy, W. E. Brady et al., “Cadherins, catenins and cell cycle regulators: impact on survival in a Gynecologic Oncology Group phase II endometrial cancer trial,” Gynecologic Oncology, vol. 123, no. 2, pp. 320–328, 2011. View at Publisher · View at Google Scholar · View at Scopus